Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027

Lyell Immunopharma, Inc.

2026-Q1 EPS reported -$1.10 revenue$2,000

Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
Cash $261M as of March 31, 2026, providing runway into Q3 2027.
PiNACLE trial for ronde-cel in 3L+ LBCL: additional data H2 2026, pivotal data mid-2027, BLA submission 2027 expected.
Phase 3 PiNACLE-H2H (ronde-cel vs standard CAR T) commenced dosing; LYL273 Phase 1 for mCRC at Dose Level 3.
Closed second $50M tranche of private placement at $25.61/share; total $100M; Smital Shah appointed CFO.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.